Tirzepatide, a synthetic derivative of gastric inhibitory polypeptide (GIP), exhibits simultaneous glucagon-like peptide-1 (GLP-1) functionality, making it a versatile compound for research. Initially developed to combat type 2 diabetes, Tirzepatide has shown additional benefits in protecting the cardiovascular system and acting as a potent weight loss agent. Research indicates that Tirzepatide can lower blood glucose levels, increase insulin sensitivity, enhance feelings of satiety, and accelerate weight loss. Ideal for research applications, Tirzepatide offers a promising tool for exploring advanced therapeutic strategies in diabetes management, cardiovascular health, and obesity treatment.